Latest

03
Jan
The problem with TAM

The problem with TAM

Total Addressable Market (TAM) is a ubiquitous metric in biotech investment pitches, used to quantify the theoretical revenue potential of
4 min read
02
Jan
The Problem with CAGR

The Problem with CAGR

Biotech investing is not for the faint-hearted. This field, ruled by unpredictability, is a theatre of sharp turns: clinical trials
7 min read
01
Jan
Fat-Tailed Distributions and Black Swan Events: Why They Matter

Fat-Tailed Distributions and Black Swan Events: Why They Matter

The concepts of fat-tailed distributions and black swan events, as popularized by Nassim Nicholas Taleb in seminal work "The
6 min read
01
Jan
Exploring Outliers: How Rare Events Shape My Thinking

Exploring Outliers: How Rare Events Shape My Thinking

Hi, I’m Sebastian, and this blog is both an indulgence and an exploration. It’s not for any one
2 min read